ONCOR PRICING INFORM HER-2/NEU BREAST CANCER RECURRENCE TEST AT $100; FIRST QUARTER LAUNCH ANTICIPATED FOLLOWING DEC. 30 PMA APPROVAL
This article was originally published in The Gray Sheet
Executive Summary
Oncor plans to offer its Inform HER-2/neu gene-based DNA test for predicting recurrence of breast cancer at a price of about $100 per determination to qualified testing laboratories following roll-out in the first quarter of 1998.